Lymph node clues may predict immunotherapy response in esophageal cancer
NCT ID NCT07533357
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will enroll 158 adults with advanced or recurrent esophageal cancer who plan to receive PD-1 inhibitor immunotherapy. Researchers want to see if a high level of a specific immune cell type (precursor exhausted T cells, or Tpex) in cancer-free lymph nodes can better predict survival than current methods. The study does not test a new treatment but aims to improve how doctors forecast treatment success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a better way to predict which patients will benefit from immunotherapy, helping doctors choose the right treatment earlier.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve outcomes. The findings may not apply to all patients or be confirmed in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can surgery for stomach or esophageal cancer cloud the mind?
- Virtual patients could revolutionize cancer drug testing
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?